Terumo Corporation
IFRS Financial Results for the Third Quarter ofthe Fiscal Year Ending March 31, 2021

－1－

IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2021
February 4, 2021
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL https://www.terumo.com/): 4543: Shinjiro Sato, President and CEO: Kenichi Hata, General Manager, Investor Relations Dept.
: +81 / 3-6742-8550

Company code number
Representative:
Please address all communications toPhone

1. Consolidated Financial Highlights for the Nine Months Ended December 31, 2020
(From April 1, 2020 to December 31, 2020)(1) Consolidated operating results(Notes: The amounts shown below ignore values of less than a million yen)

Revenue

Operating profit(Millions of yen)%

(Millions of yen)

448,628
470,144(4.6)
6.0

75,272
86,250Nine months ended December, 2020
Nine months ended December, 2019

Basic Earnings per share

Profit before tax% (Millions of yen)

(12.7)
9.9

74,92885,487

Profit for the period
attributable to theowners of the parent

Profit for the period%(Millions of yen)

(12.4)
14.0

58,502
66,762% (Millions of yen)

(12.4)
18.4

58,601
66,893

Total comprehensive
income for the period%(Millions of yen)%

(12.4)
18.4

36,07756,763(36.4)(25.4)

Diluted Earnings per share

(Yen)

(Yen)

Nine months ended December, 2020
77.63
Nine months ended December, 2019
89.64
(Notes) Adjusted operating profit: December 2020: 88,489million yen

77.44
88.40
December 2019: 98,419 million yen(2) Consolidated financial position

As of December 31, 2020
As of March 31, 2020

Total assets

Net assets

Equity attributable to theowners of the parent

Equity attributable to theowners of the parent ratio(Millions of yen)

(Millions of yen)

(Millions of yen)%

1,257,797
1,241,355

776,386
754,883

776,416
754,813

61.7
60.8

2. Dividends
Cash dividends per share
1st quarter2nd quarter3rd quarter

4th quarter

Total(Yen)(Yen)(Yen)(Yen)

(Yen)

ー

14.00
14.00

ー

14.00

28.00

ー

14.00

28.00

Fiscal Year ended March, 2020
Fiscal Year ending March, 2021
Fiscal Year ending March, 2021
(forecast)(Notes) Revision of dividends forecast : Noneー

3. Consolidated Forecast for the Fiscal Year Ending March, 2021 (From April 1, 2020 to March 31, 2021)
Revenue

Fiscal Year ending March, 2021

Adjusted operating profit

Profit for the year
attributable to the ownersof the parent

Operating profit

Earnings per share(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

(Millions of yen)

%

(Yen)

600,000(4.6)

115,000(8.0)

97,500(11.9)

75,000(12.0)

99.33(Notes) 1) Revision of forecast for fiscal year ending March, 2021 : Yes
Regarding the forecast for cumulative consolidated earnings for the fiscal year, please refer to the February 4th, 2021 press release “Terumo Revises its Full-Year Financial Guidance for FY2020”.
2) Earnings per share is calculated by taking into consideration effects of the conversion of convertible bonds in the nine months.
Assumed exchange rate for fiscal year ending March, 2021: USD1=JPY106, EUR1=JPY123（Assumed exchange rate for the fourth quarter of the fiscal year ending March, 2021: USD1=JPY104, EUR1=JPY126）

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based onlimited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results
include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

－2－

4. Condensed Consolidated Financial Statements① Condensed Consolidated Statement of Financial Position（Unit: Millions of yen）
As ofDecember 31, 2020

As ofMarch 31, 2020
AssetsCurrent assets
Cash and cash equivalents

166,898

169,760

Trade and other receivables

131,728

128,911

Other current financial assets

397

53

147,147

169,697

Current tax assets

1,745

203

Other current assets

12,68913,842

Total current assets

460,607482,470

Property, plant and equipment

264,407278,947

Goodwill and intangible assets

461,506

443,923

Inventories

Non-current assets

Investments accounted for using
the equity method
Other non-current financial assets

5,275

3,664

17,733

18,434

Deferred tax assets

27,307

26,296

Other non-current assets

4,517

4,062

Total non-current assets

780,748775,327

1,241,355

1,257,797

Total assets－3－

（Unit: Millions of yen）
As ofDecember 31, 2020

As ofMarch 31, 2020
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

88,044

69,374

Bonds and borrowings

50,324

11,728Other current financial liabilities

6,144

7,806

Current tax liabilities

11,681

8,630

395

319

Other current liabilities

55,25658,245

Total current liabilities211,845

156,105

Bonds and borrowings

195,870

243,505

Other non-current financial liabilities

31,80237,080

Deferred tax liabilities

20,36017,331

Defined benefit liabilities

18,456

17,5799289

Other non-current liabilities

8,043

9,719

Total non-current liabilities

274,626

325,305

486,472

481,411

Share capital

38,716

38,716

Capital surplus

51,85851,779Treasury shares(14,103)(7,408)Retained earnings

705,765744,756

Other components of equity(27,423)(51,428)

Total equity attributable to ownersof the parentNon-controlling interests

754,813776,416

69(29)

Total equity

754,883

776,386

1,241,355

1,257,797

Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal liabilities and equity－4－

② Condensed Consolidated Statement of Profit or Loss
For the nine months ended
December 31, 2019
470,144
211,509258,635
173,8443,593
2,134
86,2501,424
2,091（Unit: Millions of yen）
For the nine months ended
December 31, 2020
448,628
207,360
241,268
166,546
2,309
1,758
75,272
1,745
1,421

(96)

(668)

85,48718,725
66,762

74,92816,42658,502Attributable to:
Owners of the parent
Non-controlling interests
Total profit for the period

66,893(131)
66,76258,601(98)
58,502

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

89.64
88.40

77.63
77.44

Revenue
Cost of sales
Gross profit
Selling, general and administrative expenses
Other income
Other expenses
Operating profit
Finance income
Finance costs
Share of profit (loss) of investments accounted
for using the equity method
Profit before tax
Income tax expenses
Profit for the period－5－

③ Condensed Consolidated Statement of Comprehensive Income

For the nine months ended
December 31, 2019
66,762（Unit: Millions of yen）
For the nine months ended
December 31, 2020
58,502

407

1,172

(467)

139

(60)

1,311

(10,163)(24,377)

212

143

11497

(9,939)(23,736)(9,999)(22,424)

56,76336,077

Owners of the parent

56,88736,176

Non-controlling interests

(124)

(99)

56,76336,077

Profit for the period
Other comprehensive income
Items that will not be reclassified to profit or loss
Changes in financial assets measured at fair value
through other comprehensive income
Remeasurement of defined benefit plan
Total items that will not be reclassified toprofit or loss
Items that are or may be reclassified
subsequently to profit or loss
Exchange differences on translation offoreign operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Total other comprehensive income (loss)
for the period
Total comprehensive income for the period
Attributable toTotal comprehensive income for the period(Note)

Items in the above statement are net of tax.

－

6－

④ Condensed Consolidated Statements of Changes in Equity（Unit: Millions of yen）
Share
capitalBalance as of April 1, 2019

Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearnings
of equity

Noncontrollinginterests

Total

Total

38,71652,029(32,381)646,223(6,553)

698,034

78

698,113

Profit for the period

－

－

－

66,893－

66,893(131)

66,762Other comprehensive income－－－－(10,006)(10,006)

6(9,999)－－－

66,893(10,006)

56,887(124)

56,763Acquisition of treasury shares

－－(2)

－－(2)

－(2)

Disposal of treasury shares

－－

80

(18)

(61)

0－

0

Dividends－－－(20,507)－(20,507)－(20,507)

－－－

(467)

467

－

－

－－－－－－

－

159

159

－

(101)

120

82

31

132

－

132

－

(115)

17,250(260)－

16,874－

16,874－(217)

17,448(21,170)437(3,502)

159(3,342)

38,71651,812(14,933)

691,947(16,122)751,419113

751,533

Total comprehensive income

Transfer from other components ofequity to retained earnings
Change in shares of subsidiaries due
to capital increase
Share-based payments
Conversion of convertible bonds
Total transactions with the owners ofthe parent
Balance as of December 31, 2019

（Unit: Millions of yen）
Share
capitalBalance as of April 1, 2020

Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearningsof equity

Noncontrollinginterests

Total

Total

38,71651,858(14,103)705,765(27,423)754,81369

754,883

Profit for the period－－－

58,601－58,601(98)

58,502Other comprehensive income－－－－(22,424)(22,424)(0)(22,424)－－－

58,601(22,424)

36,176(99)

36,077

Acquisition of treasury shares

－－

(2)

－－(2)

－

(2)

Disposal of treasury shares

－－

96

(14)

(82)

0

－

0

Dividends－－－(21,109)－(21,109)－(21,109)

－

－

－

1,532

(1,532)

－

－－

－

(49)

99

102

35

187

－

187

－

(29)

6,501

(121)

－

6,350

－

6,350

－

(79)

6,694

(19,610)(1,580)(14,574)－(14,574)

38,716

51,779(7,408)744,756(51,428)

776,416(29)

776,386

Total comprehensive income

Transfer from other components ofequity to retained earnings
Share-based payments
Conversion of convertible bonds
Total transactions with the owners ofthe parent
Balance as of December 31, 2020－7－⑤ Segment informatition▪ Reportable segment information

Revenue and operating results of the reportable segments of the Group are described below.
▪ Changes in name of reportable segment

The segment previously named “Blood Management Company” was changed to “Blood and Cell Technologies
Company” from the fiscal year ended March 31, 2020. This change in name does not affect the segment information.
The name of reportable segment for the fiscal year ended December 31, 2019 was also revised to “Blood and Cell
Technologies Company”.
For the nine months ended December 31, 2019
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinations
Non-recurring profit orloss (Note 2)

Adjustments(Note 1)

Amountrecorded oncondensed
consolidated
financialstatements

469,976168

470,144

10,424

98,997(578)

98,419(6,153)(11,426)(440)(11,867)

CardiacandVascularCompanyGeneral
HospitalCompany

Blood andCell
Technologies
Company

263,473

127,786

78,71768,753

19,819(5,273)－Total(300)

Operating profit

86,250Finance income

1,424

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(2,091)

Profit before tax

85,487(96)(Note 1) Amounts in ‘Adjustments’ are as follows:(1) ¥168 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥(578) million adjustment to segment profit consists of ¥31 million for “inventories”.
(Note 2) ¥(300) million Non-recurring profit or loss mainly includes ¥1,180 million insurance revenue about hurricane in
Puerto Rico in 2017 and ¥(1,099) million for business reorganization expenses.

－8－

For the nine months ended December 31, 2020
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operating
profit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinations
Non-recurring profit orloss (Note 2)

Adjustments(Note 1)

Amountrecorded oncondensed
consolidated
financialstatements

448,437

191

448,628

14,43890,948(2,458)88,489(6,009)(11,211)372(10,838)

Cardiacand
VascularCompanyGeneral
HospitalCompany

Blood andCell
Technologies
Company

238,405

129,023

81,00756,032

20,476(5,201)－Total(2,378)

Operating profit

75,272Finance income

1,745

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(1,421)

Profit before tax

74,928(668)(Note 1) Amounts in ‘Adjustments’ are as follows:(1) ¥191 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥(2,458) million adjustment to segment profit consists of ¥413 million for “inventories” and ¥(1,762) million
for preparation expenses to comply with Medical Device Regulation in EU.
(Note 2) ¥(2,378) million Non-recurring profit or loss mainly includes ¥(1,838) million for the change in fair value ofcontingent consideration and ¥(383) million for business reorganization expenses.

－

9－